A prodrug form of azilsartan; reduces blood pressure and decreases PAI-1 levels in the plasma, left ventricle, and aortic wall in mice in a dose-dependent manner when administered at doses ranging from 0.1-10 mg/kg; inhibits the angiotensin II-induced pressor response in normotensive rats (ID50 = 0.12 mg/kg); reduces blood pressure and improves glucose infusion in spontaneously hypertensive rats; has more potent antiproteinuric effects in Wistar fatty rats than olmesartan medoxomil